| References: |
AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein, and is a highly targeted investigational medicine for the treatment of patients with cancers that harbor an IDH1 mutation. AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. For the detailed information of AG-120, the solubility of AG-120 in water, the solubility of AG-120 in DMSO, the solubility of AG-120 in PBS buffer, the animal experiment (test) of AG-120, the cell expriment (test) of AG-120, the in vivo, in vitro and clinical trial test of AG-120, the EC50, IC50,and affinity,of AG-120, For the detailed information of AG-120, the solubility of AG-120 in water, the solubility of AG-120 in DMSO, the solubility of AG-120 in PBS buffer, the animal experiment (test) of AG-120, the cell expriment (test) of AG-120, the in vivo, in vitro and clinical trial test of AG-120, the EC50, IC50,and affinity,of AG-120, Please contact DC Chemicals. |
